Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.

Clinical trials have shown over 60% response rate, and 52% remission rate in patients treated with Spravato® with minimal side effects.

Who can benefit from Spravato®?

Spravato® is FDA-approved to treat two specific types of depression in adults:

  • Treatment-Resistant Depression (TRD)
    Treatment-resistant depression is depression that does not improve with two or more antidepressants tried at adequate dosages and duration.
  • Major Depressive Disorder with Suicidal Ideations
    If you have major depressive disorder and have expressed suicidal thoughts or behaviors, Spravato® nasal spray may be an appropriate next step in treatment.

Spravato

50% - 70%
Response rate

62%
better social functioning

53%
better quality of life

Source:
https://www.janssenscience.com
 

Affordable, Doctor-Supervised Esketamine Therapy